OBJECTIVE:To investigate the preventive and therapeutic effect of Shuganning injection on alcoholic liver fibrosis (ALF) in model rats,and provide experimental basis for its clinical application for alcoholic liver disease. METHODS:50 rats were enrolled and intraperitoneally given mixed liquid of 60% alcohol-corn oil-pyrazole to reduce ALF model. Another 10 rats were enrolled and intraperitoneally given normal saline,as normal control group. After 16 weeks,survived model rats(n=40)were ran-domly divided into model group,positive control group(Anluo huaxian pill 0.75 g/kg,ig),Shuganning injection high-dose,medi-um-dose,low-dose groups(4.8,2.4,1.2 mL/kg,ip),8 in each group. Normal control group and model group were intraperitone-ally injected equal volume of normal saline (5 mL/kg),administration groups were given relevant medicines,once a day,for 8 weeks;and modeling was contiuously conducted at the same time. After administration,body mass of rats was weighed,and the levels of liver function indexes [aspartate aminotransferase(AST),alanine aminotransferase(ALT)] and liver fibrosis indexes [hyal-uronic acid(HA),laminin(LN),type Ⅲ procollagen(PⅢNP),type Ⅳ collagen(Ⅳ-C)] in serum of rats were detected. Liver index of rats was determined and pathological changes of liver tissue were observed. RESULTS:Compared with normal control group,body mass of rats in model group was significantly decreased(P<0.05);liver index,and liver function index,liver fibro-sis index levels in serum were significantly increased (P<0.05 or P<0.01). Liver tissue showed steatosis,hepatocyte vacuoliza-tion,a large number of fibrous tissue deposition around portal areas and other pathological changes. Compared with model group,above-mentioned changes were improved significantly in administration groups (P<0.05 or P<0.01). CONCLUSIONS:Shugan-ning injection can obviously improve liver tissue damage of model rats with ALF,showing certain preventive and therapeutic effect on alcoholic liver disease.%目的:考察舒肝宁注射液对酒精性肝纤维化(ALF)模型大鼠的防治作用,为其临床用于酒精性肝病的治疗提供实验参考.方法:取50只大鼠,每天ig 60%乙醇-玉米油-吡唑混悬液复制ALF模型;另取同批大鼠10只,ig生理盐水,作为正常对照组.连续16周后,将存活的造模大鼠(n=40)随机分为模型组、阳性对照组(安络化纤丸0.75 g/kg,ig)和舒肝宁注射液高、中、低剂量组(4.8、2.4、1.2 mL/kg,ip),每组8只.正常对照组和模型组大鼠ip等体积生理盐水(5 mL/kg),给药组大鼠给予相应药物,每天1次,连续给药8周,并同时继续进行造模处理.给药结束后,称定大鼠体质量,检测大鼠血清中肝功能指标[天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)]和肝纤维化指标[透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原(PⅢNP)和Ⅳ型胶原(Ⅳ-C)]水平,测定大鼠肝指数并观察肝组织病理变化.结果:与正常对照组比较,模型组大鼠体质量显著降低(P<0.05);肝指数以及血清中肝功能指标和肝纤维化指标水平均显著升高(P<0.05或P<0.01);肝组织出现脂肪变性、肝细胞空泡化、汇管区周围有大量纤维组织沉积等病理改变.与模型组比较,各给药组大鼠上述变化均显著改善(P<0.05或P<0.01).结论:舒肝宁注射液可明显改善ALF模型大鼠的肝组织损伤,对酒精性肝病有一定的防治作用.
展开▼
